Hot off the press. Updated CAP HER2 biomarker templates/guidelines as described for selection of Trastuzumab (modified breast/serous ca criteria) vs Trastuzumab-deruxtecan (gastic/DESTINY trial criteria). Thoughts? Serous vs other? What are your plans? #pathsky

documents.cap.org/protocols/Gy...